Parambir S. Dulai|Corey A. Siegel|Marla Dubinsky
Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease
Dartmouth–Hitchcock Medical Center|Dartmouth–Hitchcock Medical Center|Cedars-Sinai Medical Center
antitumor necrosis factor agents considered vital component treatment algorithm pediatric inflammatory bowel disease despite clear benefit agents realignment treatment goals achieve early mucosal healing decision initiate therapy often delayed due uncertainties regarding risks benefits purpose review summarize currently available data regarding antitumor necrosis factor agents pediatric inflammatory bowel disease specifically review expected efficacy crohns disease ulcerative colitis likelihood side effects associated agents addition address barriers physicians face communicating data help identify pediatric patients parents involved shared decisionmaking process creation new decision aid option grid hope allow clear line communication bedside helping patients parents make difficult treatment decisions